PAR PHARM
GenericsPAR PHARM is a generic drug manufacturer focused on Dermatology, Cardiovascular, Infectious Disease.
PAR PHARM's Key Drugs
PAR PHARM's core commercial portfolio centers on DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, spanning Dermatology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
PAR PHARM's Recent FDA Approvals
New NDA/BLA approvals for PAR PHARM over the last two years — novel drugs only, excluding generics and label supplements.
PAR PHARM's Therapeutic Areas
PAR PHARM's approved drugs and pipeline span 3 therapeutic areas, led by Dermatology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PAR PHARM's Top Competitors
PAR PHARM's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PAR PHARM Pipeline Snapshot
PAR PHARM has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 1971-11-30
- Latest
- 2020-12-23
- Applications
- 91